A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 57-62

  Clément Duchêne, Christelle ^a,b   Natale, Ronald B ^c   Jahan, Thierry ^d   Krupitskaya, Yelena ^a   Osarogiagbon, Raymond ^e   Sanborn, Rachel E ^f   Bernstein, Eric D ^f   Dudek, Arkadiusz Z ^g   Latz, Jane E ^h   Shi, Peipei ^h   Wakelee, Heather A ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Enzastaurin; Erlotinib; NSCLC

Indexed keywords

ENZASTAURIN; ERLOTINIB; HEMOGLOBIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; COUGHING; DECREASED APPETITE; DECUBITUS; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL PAIN; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; NAIL INFECTION; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN INFECTION; SMOKING; SUPERIOR CAVA VEIN OBSTRUCTION; SYNCOPE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84866154541     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.003     Document Type: Article

References (51)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132. National Cancer Institute of Canada Clinical Trials Group.
4. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362. The TAX 320 Non-Small Cell Lung Cancer Study Group.
5. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
6. Scagliotti G., Brodowicz T., Shepherd F.A., Zielinski C., Vansteenkiste J., Manegold C., et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
7. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
8. Balendran A., Hare G.R., Kieloch A., Williams M.R., Alessi D.R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000, 484:217-223.
9. Partovian C., Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 2004, 16:951-957.
10. Zhang J., Anastasiadis P.Z., Liu Y., Thompson E.A., Fields A.P. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 2004, 279:22118-22123.
11. Keyes K.A., Mann L., Sherman M., Galbreath E., Schirtzinger L., Ballard D., et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004, 53:133-140.
12. Takahashi T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999, 18:2221-2230.
13. Yoshiji H., Kuriyama S., Ways D.K., Yoshii J., Miyamoto Y., Kawata M., et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999, 59:4413-4418.
14. Herbst R.S., Oh Y., Wagle A., Lahn M. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 2007, 13(15 Pt 2):s4641-s4646.
15. Gökmen-Polar Y., Murray N.R., Velasco M.A., Gatalica Z., Fields A.P. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 2001, 61:1375-1381.
16. Engers R., Mrzyk S., Springer E., Fabbro D., Weissgerber G., Gernharz C.D., et al. Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br J Cancer 2000, 82:1063-1069.
17. Tsai J.H., Hsieh Y.S., Kuo S.J., Chen S.T., Yu S.Y., Huang C.Y., et al. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett 2000, 161:171-175.
18. Koren R., Ben Meir D., Langzam L., Dekel Y., Konichezky M., Baniel J., et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 2004, 11:321-326.
19. Clark A.S., West K.A., Blumberg P.M., Dennis P.A. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003, 63:780-786.
20. Lahn M., McClelland P., Ballard D., Mintze K., Thornton D., Sandusky G. Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. Histopathology 2006, 49:429-431.
21. Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., Bailey S.N., et al. The protein kinase Cbeta-selective inhibitor Enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005, 65:7462-7469.
22. Kreisl T.N., Kotliarova S., Butman J.A., Albert P.S., Kim L., Musib L., et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 2010, 12:181-189.
23. Robertson M.J., Kahl B.S., Vose J.M., de Vos S., Laughlin M., Flynn P.J., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741-1746.
24. Carducci M.A., Musib L., Kies M.S., Pili R., Truong M., Brahmer J.R., et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006, 24:4092-4099.
25. Oh Y., Herbst R.S., Burris H., Cleverly A., Musib L., Lahn M., et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008, 26:1135-1141.
26. Fields A.P., Murray N.R. Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul 2008, 48:166-178.
27. Wick W., Puduvalli V.K., Chamberlain M.C., van den Bent M.J., Carpentier A.F., Cher L.M., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28:1168-1174.
28. Morgillo F., Martinelli E., Troiani T., Laus G., Pepe S., Gridelli C., et al. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 2008, 7:1698-1707.
29. Tekle C., Giovannetti E., Sigmond J., Graff J.R., Smid K., Peters G.J. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008, 99:750-759.
30. Camidge D.R., Eckhardt G.S., Gore L., O'Bryant C.L., Leong S., Basche M., et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008, 19:77-84.
31. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
32. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529. SATURN investigators.
33. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
34. Padda S.K., Krupitskaya Y., Chhatwani L., Fisher G.A., Colevas A.D., San Pedro-Salcedo M., et al. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 69:1013-1020.
35. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
36. Leemis L.M., Trivedi K.S. A comparison of approximate interval estimators for the Bernoulli parameter. Am Stat 1996, 50:63-68.
37. Herbst R.S., Ansari R., Bustin F., Flynn P., Hart L., Otterson G.A., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
38. Gelardi T., Caputo R., Damiano V., Daniele G., Pepe S., Ciardiello F., et al. Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008, 99:473-480.
39. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
40. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
41. Mina L., Krop I., Zon R.T., Isakoff S.J., Schneider C.J., Yu M., et al. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs 2009, 27:565-570.
42. Chiappori A., Bepler G., Barlesi F., Soria J.C., Reck M., Bearz A., et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:369-375.
43. Richards D.A., Kuefler P.R., Becerra C., Wilfong L.S., Gersh R.H., Boehm K.A., et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs 2011, 29:144-153.
44. Casey E.M., Harb W., Bradford D., Bufill J., Nattam S., Patel J., et al. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaive patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol 2010, 5:1815-1820.
45. Liu J., Kuo W.L., Seiwert T.Y., Lingen M., Ciaccio M.F., Jones R.B., et al. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 2011, 33:1774-1782.
46. Ghobrial I.M., Munshi N.C., Harris B.N., Shi P., Porter N.M., Schlossman R.L., et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011, 86:573-578.
47. Schmidinger M., Szczylik C., Sternberg C.N., Kania M., Kelly C.S., Decker R., et al. Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2011, (June). [Epub ahead of print].
48. Lee S.H., Chen T., Zhou J., Hofmann J., Bepler G. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer 2010, 11:169-175.
49. Körner A., Mudduluru G., Manegold C., Allgayer H. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer 2010, 103:802-811.
50. Kuo W.L., Liu J., Mauceri H., Vokes E.E., Weichselbaum R., Rosner M.R., et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther 2010, 9:2814-2824.
51. Usha L., Sill M.W., Darcy K.M., Benbrook D.M., Hurteau J.A., Michelin D.P., et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011, 121:455-461.